Search research articles
Contact Us
Filters
Showing results (21-30 of 51) with videos related to
Page
of 6
Sort By:
Cancer Chemotherapy and Pharmacology
|
February 9, 2000
Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid
E Schleyer, K L Rudolph, J Braess, et al.
Leukemia
|
June 1, 1995
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative
E Schleyer, J Braess, B Ramsauer, et al.
Annals of Hematology
|
June 10, 1998
Chronic systemic aspergillosis in a patient with acute myeloid leukemia
W Kern, J Braess, H Bertz, et al.
Leukemia
|
February 16, 2000
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities
W Kern, C Schoch, T Haferlach, et al.
Deutsche Medizinische Wochenschrift (1946)
|
May 28, 2009
[Modern leukemia diagnosis in adults]
B Heilmeier, K Spiekermann, S Bohlander, et al.
British Journal of Haematology
|
June 10, 2000
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine
J Braess, C Wegendt, G Jahns-Streubel, et al.
Leukemia
|
October 10, 1998
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics
J Braess, M Freund, A Hanauske, et al.
Annals of Hematology
|
July 28, 2001
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias
W Kern, E Schleyer, J Braess, et al.
MMW Fortschritte Der Medizin
|
August 3, 2007
[Fortuitous finding: thrombocytopenia and thrombocytosis]
K H Metzeler, J Braess, K Spiekermann, et al.
Leukemia
|
April 1, 1996
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve
E Schleyer, S Kühn, H Rührs, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 51) with videos related to
Sort By:
Page
of 6
Cancer Chemotherapy and Pharmacology
|
February 9, 2000
Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid
E Schleyer, K L Rudolph, J Braess, et al.
Leukemia
|
June 1, 1995
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative
E Schleyer, J Braess, B Ramsauer, et al.
Annals of Hematology
|
June 10, 1998
Chronic systemic aspergillosis in a patient with acute myeloid leukemia
W Kern, J Braess, H Bertz, et al.
Leukemia
|
February 16, 2000
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities
W Kern, C Schoch, T Haferlach, et al.
Deutsche Medizinische Wochenschrift (1946)
|
May 28, 2009
[Modern leukemia diagnosis in adults]
B Heilmeier, K Spiekermann, S Bohlander, et al.
British Journal of Haematology
|
June 10, 2000
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine
J Braess, C Wegendt, G Jahns-Streubel, et al.
Leukemia
|
October 10, 1998
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics
J Braess, M Freund, A Hanauske, et al.
Annals of Hematology
|
July 28, 2001
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias
W Kern, E Schleyer, J Braess, et al.
MMW Fortschritte Der Medizin
|
August 3, 2007
[Fortuitous finding: thrombocytopenia and thrombocytosis]
K H Metzeler, J Braess, K Spiekermann, et al.
Leukemia
|
April 1, 1996
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve
E Schleyer, S Kühn, H Rührs, et al.
Page
of 6